<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650975</url>
  </required_header>
  <id_info>
    <org_study_id>D001747-01</org_study_id>
    <nct_id>NCT00650975</nct_id>
  </id_info>
  <brief_title>ThromboAblation in Acute Myocardial Infarction</brief_title>
  <acronym>TAAMI</acronym>
  <official_title>ThromboAblation in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KCRI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Assess whether excimer laser coronary atherectomy (ELCA) before direct infarct-related
           artery (IRA) stenting results in improved reperfusion success in patients presenting
           with acute ST wave elevation myocardial infarction (STEMI) and angiographically evident
           thrombus.

        2. Validate an ELCA technique for the treatment of STEMI, at high-volume centers
           experienced in the treatment of acute myocardial infarction (AMI).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment rate.
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Blush Grade 3 (MBG3) ST-Resolution MACE</measure>
    <time_frame>60 minutes - 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>ST Elevation Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>ELCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser Thromboablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTCA (Direct Stenting)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Thromboablation</intervention_name>
    <description>Laser Thromboablation using the Spectranetics CVX-300® excimer laser system</description>
    <arm_group_label>ELCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTCA (Direct Stenting)</intervention_name>
    <description>Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use</description>
    <arm_group_label>PTCA</arm_group_label>
    <other_name>PCI</other_name>
    <other_name>Direct Stenting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Electrocardiographic inclusion criteria: (baseline 12-lead ECG recorded at 25 mm/second
        upon arrival at investigational center)

          -  STEMI within 12 hours of symptom onset, with ≥ 2 mm ST segment elevation in two or
             more leads and minimum ≥ 3 mm ST segment elevation in one lead.

        Angiographic inclusion criteria after crossing with guidewire:

          -  IRA is a native coronary artery; and,

          -  Reference vessel diameter 2.5 - 4.0 mm; and,

          -  TIMI 0 or 1 flow with any TIMI thrombus grade; or,

          -  TIMI 2 or 3 flow with TIMI thrombus grade 3 or greater

        Exclusion Criteria:

          -  Patient unwilling or unable to give informed consent

          -  Previous MI in the distribution of the current IRA

          -  Previous CABG

          -  Contraindications to PCI

               -  allergy(s) to intended study medications

               -  contraindicated for stent implantation

          -  Active bleeding or coagulopathy

          -  Patient in cardiogenic shock (&lt;90mmHg SBP and/or requiring IABP or vasopressors)

          -  Known left ventricular ejection fraction (EF) &lt;30%

          -  Fibrinolytic administered before PCI

          -  Renal insufficiency (creatinine &gt;2.0mg/dl)

          -  Current vitamin K antagonist therapy or known INR &gt;1.5

          -  Known thrombocytopenia - platelets &lt;100,000 cell count

          -  Patient has Left Bundle Branch Block (LBBB) or pacemaker rhythm

          -  Known history of hemorrhagic stroke (CVA or TIA) &lt;2 years before screening

          -  Known or suspected pregnancy

          -  Current cancer disease

          -  Comorbidity where survival is anticipated to be &lt;1 year.

          -  No future patient cooperation expected

          -  Patient is participating in another clinical study

          -  Patient &lt;18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariusz Dudek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haemodynamics and Angiocardiography Medical College Jagiellonian University University Hospital in Krakow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gornoslaskie Centrum Medyczne 3rd Dept of Cardiology</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University College of Medicine, Institute of Cardiology John Paul II Hospital</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haemodynamics and Angiocardiography Medical College Jagiellonian University University Hospital in Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital No. 1 1st Dept. of Cardiology</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology Hemodynamics dept., Cardiac Catheterization Laboratory</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>William Kerker, Sr. Manager, Clinical Applications Research</name_title>
    <organization>Spectranetics Corporation</organization>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Laser</keyword>
  <keyword>Thrombus</keyword>
  <keyword>Thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

